Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of “Hold” from Analysts

Share on StockTwits

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given an average rating of “Hold” by the nine brokerages that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $11.80.

A number of analysts have issued reports on the company. Northland Securities reissued a “buy” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, August 3rd. Morgan Stanley raised their target price on Ironwood Pharmaceuticals from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Credit Suisse Group decreased their target price on Ironwood Pharmaceuticals from $12.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, June 1st. BidaskClub raised Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday. Finally, ValuEngine lowered Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, August 7th.

In related news, Director Julie Mchugh sold 7,950 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $9.77, for a total transaction of $77,671.50. Following the completion of the sale, the director now owns 123,107 shares of the company’s stock, valued at $1,202,755.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its stake in Ironwood Pharmaceuticals by 361.3% during the second quarter. Principal Financial Group Inc. now owns 200,443 shares of the biotechnology company’s stock worth $2,069,000 after purchasing an additional 156,987 shares during the last quarter. Handelsbanken Fonder AB bought a new stake in Ironwood Pharmaceuticals during the second quarter worth about $279,000. Nuveen Asset Management LLC lifted its stake in Ironwood Pharmaceuticals by 50.5% during the second quarter. Nuveen Asset Management LLC now owns 1,490,293 shares of the biotechnology company’s stock worth $15,380,000 after purchasing an additional 500,309 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Ironwood Pharmaceuticals by 12.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,105,073 shares of the biotechnology company’s stock worth $11,405,000 after purchasing an additional 119,395 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 63.7% during the second quarter. AQR Capital Management LLC now owns 440,921 shares of the biotechnology company’s stock worth $4,550,000 after purchasing an additional 171,531 shares during the last quarter.

Shares of IRWD opened at $10.15 on Wednesday. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 16.64 and a beta of 1.47. The stock has a 50 day moving average of $9.95 and a 200 day moving average of $10.21. Ironwood Pharmaceuticals has a 12 month low of $7.91 and a 12 month high of $14.10.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.16 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.08. Ironwood Pharmaceuticals had a negative return on equity of 160.69% and a net margin of 22.74%. The company had revenue of $89.43 million during the quarter, compared to the consensus estimate of $85.38 million. During the same period last year, the business posted $0.10 earnings per share. Ironwood Pharmaceuticals’s revenue was down 12.5% on a year-over-year basis. Sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.51 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Read More: What is Compound Annual Growth Rate (CAGR)?

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AQR Capital Management LLC Has $847,000 Stock Holdings in United Natural Foods Inc
AQR Capital Management LLC Has $847,000 Stock Holdings in United Natural Foods Inc
AQR Capital Management LLC Sells 123,807 Shares of United Natural Foods Inc
AQR Capital Management LLC Sells 123,807 Shares of United Natural Foods Inc
Nuveen Asset Management LLC Sells 37,360 Shares of Big Lots, Inc.
Nuveen Asset Management LLC Sells 37,360 Shares of Big Lots, Inc.
AQR Capital Management LLC Invests $973,000 in Hometrust Bancshares Inc
AQR Capital Management LLC Invests $973,000 in Hometrust Bancshares Inc
Nuveen Asset Management LLC Invests $11.66 Million in Ovintiv
Nuveen Asset Management LLC Invests $11.66 Million in Ovintiv
Nuveen Asset Management LLC Trims Stock Position in Zillow Group Inc
Nuveen Asset Management LLC Trims Stock Position in Zillow Group Inc


© 2006-2020 Ticker Report